Join the Oncology Voice Network. Join for Free
The Most Common (or NOT) Interview questions and How to Handle Them
Medical Science Liaison interview tips MSL interview questions building therapeutic area knowledge interview anxiety techniques aligning with company values

The Most Common (or NOT) Interview questions and How to Handle Them


Share This Article


Summary

In this episode, Anita Carvalho joins MSL Talk to share invaluable interview tips for aspiring Medical Science Liaisons. Anita emphasizes the importance of thoroughly researching the company and effectively presenting one's resume. She offers strategies for selling oneself during interviews and tackling common challenges, including specific MSL interview questions. The discussion covers building relationships, mastering therapeutic area knowledge, and managing interview anxiety using techniques like the STAR method. Anita also highlights the significance of aligning with company values and proper post-interview etiquette. The episode concludes with closing remarks and gratitude.

Check out my latest podcast with Anita Carvalho, Talent Acquisition Specialist at FerGene. We discuss the most common (and not so common) MSL interview questions and how to handle them.

We discuss:

 What basic interview questions should you expect
 What are some MSL specific interview questions
 What are some “not so” common and even wacky interview questions
 What are behavioral (situational) interview questions and how to handle them

Click for Source
Medical Science Liaison interview tips, MSL interview questions, building therapeutic area knowledge, interview anxiety techniques, aligning with company values

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Article
Confounding factors in exposure–response analyses and mitigation strategies for monoclonal antibodies in oncology
OVN Avatar Sonoko Kawakatsu, René Bruno, Matts Kågedal, Chunze Li, Sandhya Girish, Amita Joshi, Benjamin Wu

Confounding factors in exposure–response analyses and mitigation strategies for monoclonal antibodies in oncology

Article
Level of evidence used in recommendations by the National Comprehensive Cancer Network (NCCN) guidelines beyond Food and Drug Administration approvals
OVN Avatar R. Kurzrock, L.A. Gurski, R.W. Carlson, D.S. Ettinger, S.M. Horwitz, S.K. Kumar, L. Million, M. von Mehren, A.B. Benson III

Level of evidence used in recommendations by the National Comprehensive Cancer Network (NCCN) guidelines beyond Food and Drug Administration approvals

Article
EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for hematological malignancies
OVN Avatar Barbara Kiesewetter , Nathan I Cherny, Nicolas Boissel, Francesco Cerisoli, Urania Dafni, Elisabeth G E de Vries, Paolo Ghia, Nicola Gökbuget, Verónica González-Calle, Brian Huntly, Ulrich Jäger, Nicola Jane Latino, Jean-Yves Douillard, Luca Malcovati, Ma

EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for hematological malignancies

Article
The First 2 Years of Biosimilar Epoetin for Cancer and Chemotherapy-Induced Anemia in the U.S.: A Review from the Southern Network on Adverse Reactions
OVN Avatar Charles L. Bennett , Sumimasa Nagai , Andrew C. Bennett , Shamia Hoque , Chadi Nabhan , Martin W. Schoen , William J. Hrushesky , Stefano Luminari , Paul Ray , Paul R. Yarnold , Bart Witherspoon , Josh Riente , Laura Bobolts , John Brusk , Rebecca Tombles

The First 2 Years of Biosimilar Epoetin for Cancer and Chemotherapy-Induced Anemia in the U.S.: A Review from the Southern Network on Adverse Reactions

Article
Large pharma companies reduced headcounts by more than 22K in 2025 as $300B patent cliff looms
OVN Avatar Angus Liu

Large pharma companies reduced headcounts by more than 22K in 2025 as $300B patent cliff looms

Article
Challenges and Opportunities in Dose Finding in Oncology and Immuno-oncology
OVN Avatar Yan Ji, Jin Y. Jin, David M. Hyman, Geoffrey Kim and Ajit Suri

Challenges and Opportunities in Dose Finding in Oncology and Immuno-oncology

Explore OVN